Author profile
University of British Columbia
Physiologically based pharmacokinetic (PBPK) models used in radiopharmaceutical therapy (RPT) and theranostic digital twins are rapidly increasing in size and mechanistic detail, often containing tens to hundreds of parameters. While such models fit imaging a...
Radiopharmaceutical therapies (RPTs) effectively treat metastatic castration-resistant prostate cancer, yet injected radioactivities remain empirically prescribed. Although physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) models can separ...
Existing "one-size-fits-all" approaches in PSMA radiopharmaceutical therapies (RPTs) fail to account for critical inter-patient variabilities, risking under- or over-treatment. To address this, we are developing theranostic digital twins (TDTs) for reliable p...
Computational nuclear oncology (CNO) methods are advancing rapidly but often developed in isolated tools and workflows that are difficult to reproduce, compare, and share. This fragmentation limits virtual studies and slows translation of physiologically base...
To develop and evaluate a radiomic phenotyping and multi-lesion aggregation scheme to derive patient-level biomarkers for identifying progressive disease and predicting time-to-progression (TTP) in diffuse large B-cell lymphoma (DLBCL).